# monarchE (NCT03155997)

> Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03155997
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Cancer
- Interventions: Abemaciclib; Standard Adjuvant Endocrine Therapy
- Enrollment: 5637
- Primary outcome: Invasive Disease Free Survival (IDFS)

## Commentary we found

- X threads: 277
- YouTube: 189
- Podcasts: 161
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=monarche-nct03155997

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03155997", "email": "<work email>"}; the inbox owner confirms by the emailed link.